A UK-based drugmaker has agreed to pay a record $1.4 billion settlement to the US government in order to end criminal and civil probes into allegations of illegal marketing of opioid addiction treatment medication, according to the Justice Department.
The settlement with Reckitt Benckiser Group will include multiple investigations into a subsidiary, Indivior.
Suboxone, which proved to be a blockbuster-selling drug for Indivior, is an addiction-fighting medication that also contains opioids.
On April 9, a federal grand jury in Virginia indicted Indivior for "Allegedly engaging in an illicit nationwide scheme to increase prescriptions of Suboxone," according to the DOJ. The company denied the charges and trial is scheduled to start in May 2020.
Federal prosecutors charged that Indivior allegedly marketed a version of Suboxone to medical professionals as less addictive and safer than other drugs containing its active ingredient, the opioid buprenorphine, according to the DOJ statement.
Included in the settlement is an immunity agreement, while RB Group will forfeit $647 million of proceeds from the sale of Indivior - nor will it manufacture, market or sell Schedule 1 - 3 controlled substances for three years.
The trial against the RB Group's former subsidiary Invidior is still slated to start next May. Thursday's settlement was only with RB Group, and not Indivior.
https://www.zerohedge.com/news/2019-07-12/drugmaker-pays-largest-opioid-settlement-history-make-investigations-go-away
The settlement with Reckitt Benckiser Group will include multiple investigations into a subsidiary, Indivior.
Suboxone, which proved to be a blockbuster-selling drug for Indivior, is an addiction-fighting medication that also contains opioids.
On April 9, a federal grand jury in Virginia indicted Indivior for "Allegedly engaging in an illicit nationwide scheme to increase prescriptions of Suboxone," according to the DOJ. The company denied the charges and trial is scheduled to start in May 2020.
Federal prosecutors charged that Indivior allegedly marketed a version of Suboxone to medical professionals as less addictive and safer than other drugs containing its active ingredient, the opioid buprenorphine, according to the DOJ statement.
Included in the settlement is an immunity agreement, while RB Group will forfeit $647 million of proceeds from the sale of Indivior - nor will it manufacture, market or sell Schedule 1 - 3 controlled substances for three years.
The trial against the RB Group's former subsidiary Invidior is still slated to start next May. Thursday's settlement was only with RB Group, and not Indivior.
https://www.zerohedge.com/news/2019-07-12/drugmaker-pays-largest-opioid-settlement-history-make-investigations-go-away
No comments:
Post a Comment